ACTUATE THERAPEUTICS, INC. 8-K

What Happened

• Actuate Therapeutics, Inc. held a virtual Annual Meeting of Stockholders on May 21, 2026 and filed an 8-K on May 22, 2026 reporting the results.
• Two Class II director nominees were elected to three-year terms (through the 2029 Annual Meeting): Aaron G.L. Fletcher, Ph.D., and Jason Keyes.
• Stockholders also ratified the appointment of Crowe LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Aaron G.L. Fletcher, Ph.D.: For 14,877,247; Withheld 1,883,025; Broker Non‑Votes 1,871,309.
• Jason Keyes: For 16,727,875; Withheld 32,397; Broker Non‑Votes 1,871,309.
• Ratification of Crowe LLP: For 18,571,817; Against 50,023; Abstain 9,741.
• Each elected director will serve until the 2029 Annual Meeting and until their successors are duly elected and qualified.

Why It Matters

• Board continuity: Election of the two Class II directors confirms management’s current board composition for the next three years, which can affect governance and strategic oversight.
• Audit clarity: Ratification of Crowe LLP establishes the independent accounting firm for fiscal 2026, a routine but important approval for financial reporting consistency and investor confidence.